Research programme: protein kinase inhibitors - Deciphera Pharmaceuticals

Drug Profile

Research programme: protein kinase inhibitors - Deciphera Pharmaceuticals

Alternative Names: DCC 2721; DCC-2157; DP-3407; DP-3429; DP-3556; DP-3590; DP-4178; DP-4610; DP-4904

Latest Information Update: 06 Mar 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Deciphera Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Colony stimulating factor inhibitors; Macrophage colony stimulating factor receptor antagonists; P38 mitogen-activated protein kinase inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c met inhibitors; Proto oncogene protein c-kit inhibitors; TIE 2 receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Gastrointestinal stromal tumours

Highest Development Phases

  • Preclinical Cancer metastases; Gastrointestinal stromal tumours; Solid tumours
  • Discontinued Autoimmune disorders; Inflammation; Rheumatoid arthritis

Most Recent Events

  • 06 Mar 2014 Discontinued - Preclinical for Autoimmune disorders in USA (PO)
  • 06 Mar 2014 Discontinued - Preclinical for Inflammation in USA (PO)
  • 06 Mar 2014 Discontinued - Preclinical for Rheumatoid arthritis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top